Eupraxia Pharmaceuticals Stock Debt To Equity

EPRXFDelisted Stock  USD 2.79  0.04  1.45%   
Eupraxia Pharmaceuticals fundamentals help investors to digest information that contributes to Eupraxia Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eupraxia Pink Sheet. The fundamental analysis module provides a way to measure Eupraxia Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eupraxia Pharmaceuticals pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eupraxia Pharmaceuticals Company Debt To Equity Analysis

Eupraxia Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Eupraxia Pharmaceuticals Debt To Equity

    
  0.42 %  
Most of Eupraxia Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eupraxia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

According to the company disclosure, Eupraxia Pharmaceuticals has a Debt To Equity of 0.424%. This is 99.21% lower than that of the Healthcare sector and 97.81% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 99.13% higher than that of the company.

Eupraxia Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.
Eupraxia Pharmaceuticals is currently under evaluation in debt to equity category among its peers.

Eupraxia Fundamentals

About Eupraxia Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eupraxia Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eupraxia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eupraxia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Eupraxia Pink Sheet

If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Commodity Directory
Find actively traded commodities issued by global exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges